BMY News and Press, Bristol-Myers Squibb Company From 05/06/24

Application based on results from CheckMate -67T, the first Phase 3 trial of the subcutaneous formulation of nivolumab to evaluate and demonstrate noninferior pharmacokinetics, efficacy and consistent safety vs. its intravenous formulation Subcutaneous nivolumab has potential to be th...

Application based on results from the CheckMate -8HW study, in which Opdivo plus Yervoy demonstrated statistically significant and clinically meaningful improvement in progression-free survival compared to investigator’s choice of chemotherapy European Medicin...

2024-05-04 15:30:00 ET Read the full article on Seeking Alpha For further details see: Pharma R&D productivity seen improving for the first time in years - Deloitte

2024-05-03 09:30:00 ET Some investors view growth or momentum stocks as the key to multi-bagger returns. Others prefer to deep-sea dive for beaten-down assets with rebound potential. The compounding effect of dividend reinvestment over enough time can potentially make it possible to turn $1...

2024-05-03 07:15:00 ET It's a reasonable question: If you'd invested $1,000 in pharmaceutical specialist Bristol Myers Squibb (NYSE: BMY) five years ago in 2019, how much would you have today? You might ask that if you've been thinking of investing in the company or holding its ...

2024-05-02 21:01:06 ET Summary Bristol-Myers Squibb's share price reached new all-time highs in 2022, driven by a strong pipeline and new approvals. However, doubts arose about the company's ability to close the patent gap and achieve growth, leading to a sell-off. The company...

2024-05-02 15:32:05 ET Summary CytomX Therapeutics, Inc. results from phase 1a dose-escalation study, using CX-904 for the treatment of patients with EGFR expressing solid tumors, expected with Q1 2024 earnings on May 8, 2024. Pending positive data, plus at the discretion of partn...

2024-05-02 15:04:30 ET More on Bristol Myers, Schrödinger Schrödinger, Inc. (SDGR) Q1 2024 Earnings Call Transcript Schrödinger, Inc. 2024 Q1 - Results - Earnings Call Presentation Bristol Myers Squibb: Tough Times Continue Schrodinger tumbles ...

2024-05-02 07:14:01 ET Summary Pfizer's Q1 2023 results beat market forecasts, with strong revenue growth and cost management improvements. I think it's the turning point for PFE stock - read on. The company expects continued growth from non-COVID drugs and anticipates significant...

2024-05-02 07:00:00 ET Summary Value investors have been frustrated as growth stocks have outperformed for the past 15 years. Value investing is a long-term strategy that requires patience and a focus on fundamentals. Three blue-chip stocks, Bristol-Myers, Zoetis, and Monster ...